AnalystsLee HambrightLee Hambright's Stock Forecasts
AnalystsLee Hambright
Analyst Ranking
Top 29%
#1427 out of 4923 analysts
Average Return
+12.93%
Win Rate
86%12 out of 14
Risk vs Reward
Poor
Good
Lee Hambright's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Dexcom IncDXCM | +73.52% | $79.14 | $137.32 | 2022-07-14 - 2023-07-14 | Buy |
Insulet CorpPODD | +31.29% | $239.30 | $314.18 | 2024-11-05 - 2025-06-30 | Buy |
Intuitive Surgical IncISRG | +31.04% | $307.84 | $403.39 | 2023-05-30 - 2024-05-30 | Buy |
Boston Scientific CorpBSX | +26.22% | $85.10 | $107.41 | 2024-10-23 - 2025-06-30 | Buy |
Edwards Lifesciences CorpEW | +24.63% | $21.67 | $27.00 | 2014-12-03 - 2015-12-04 | Buy |
Lee Hambright Analyst Color
Get additional color on Lee Hambright's coverage of popular stocks
Lee Hambright's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Medtronic PLCMDT | 2 | Buy | $97.00 | +11.28% | Maintains | 7 months ago |
Insulet CorpPODD | 1 | Buy | $300.00 | -4.51% | Initiates Coverage On | 8 months ago |
Tandem Diabetes Care IncTNDM | 1 | Buy | $42.00 | +125.32% | Initiates Coverage On | 8 months ago |
Dexcom IncDXCM | 2 | Buy | $86.00 | -1.48% | Maintains | 8 months ago |
Boston Scientific CorpBSX | 1 | Buy | $100.00 | -6.90% | Maintains | 8 months ago |
Abbott LaboratoriesABT | 2 | Buy | $138.00 | +1.46% | Maintains | 8 months ago |
Intuitive Surgical IncISRG | 2 | Buy | $365.00 | N/A | Maintains | 2 years ago |
Zimmer Biomet Holdings IncZBH | 1 | Hold | $152.00 | N/A | Maintains | 2 years ago |
Johnson & JohnsonJNJ | 1 | Hold | $183.00 | N/A | Downgrades | 3 years ago |
Stryker CorpSYK | 1 | Buy | $295.00 | N/A | Upgrades | 3 years ago |
Edwards Lifesciences CorpEW | 3 | Buy | $135.00 | N/A | Upgrades | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.